title: Action of a homogeneous hydrogenation catalyst on living Tetrahymena mimbres cells.
abstract: Various conditions were tested in an attempt to hydrogenate the unsaturated fatty acids of living Tetrahymena mimbres with the homogeneous catalyst palladium di-(sodium alizarine monosulfonate) without causing serious damage to the cells. Using a low (20 micrograms/ml) catalyst concentration in the external medium, hydrogenation of greater than 20% of surface membrane lipid double bonds were obtained, but hydrogenation of intracellular membranes was minimal. When exposed to H2, cells preincubated with inactive catalyst for several hours and visibly loaded with the catalyst lost viability as soon as hydrogenation exceeded trace levels. Material secreted by Tetrahymena into their medium effectively inhibited hydrogenation of added oleic acid, normally a good substrate. Mucus secreted by the cells, soluble proteins isolated from cell homogenates, bovine serum albumin, and cysteine were also inhibitory, but the inhibition could be overcome by employing higher catalyst concentrations. Although some enzymatic retroconversion of saturated lipids back to unsaturated lipids appeared to take place, the scale of the conversion was small, and further experimentation will be required to understand the mechanism involved. The selective hydrogenation of surface membranes achieved by these methods may be especially useful to those interested in fluidity effects on plasma membrane properties.
authors.affiliation: Department of Botany, University of Texas, Austin 78713.
authors.forename: Y
authors.initials: Y
authors.lastname: Pak
authors.forename: F
authors.initials: F
authors.lastname: Joó
authors.forename: L
authors.initials: L
authors.lastname: Vigh
authors.forename: A
authors.initials: A
authors.lastname: Katho
authors.forename: G A
authors.initials: GA
authors.lastname: Thompson
mesh_terms: D000818:Animals; D002462:Cell Membrane / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D003545:Cysteine / Q000494:pharmacology; D005231:Fatty Acids, Unsaturated / Q000378:metabolism*; D006859:Hydrogen / Q000378:metabolism / Q000494:pharmacology; D007425:Intracellular Membranes / Q000378:metabolism; D008563:Membrane Lipids / Q000378:metabolism*; D009093:Mucus / Q000502:physiology; D019301:Oleic Acid; D009829:Oleic Acids / Q000378:metabolism; D009942:Organometallic Compounds / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D010743:Phospholipids / Q000378:metabolism; D012710:Serum Albumin, Bovine / Q000494:pharmacology; D013768:Tetrahymena / Q000378:metabolism* / Q000648:ultrastructure
chemical_list: D005231:Fatty Acids, Unsaturated; D008563:Membrane Lipids; D009829:Oleic Acids; D009942:Organometallic Compounds; D010743:Phospholipids; D012710:Serum Albumin, Bovine; D019301:Oleic Acid; C044770:palladium sulfonated alizarine; D006859:Hydrogen; D003545:Cysteine